Cubist Systematic Strategies LLC Buys 1,026,291 Shares of Haleon PLC Sponsored ADR $HLN

Key Points

• Cubist Systematic Strategies LLC significantly increased its stake in Haleon PLC by 243.4%, owning 1,447,922 shares worth approximately $14.9 million after acquiring over a million additional shares in the first quarter.
• Haleon recently announced a semi-annual dividend of $0.0555 per share, reflecting a yield of 190.0%, which is an increase from its previous dividend payout.
• Haleon's stock has shown a slight increase of 1.2%, with the current trading price around $9.81 and an average target price of $12.33 among analysts.

Cubist Systematic Strategies LLC lifted its stake in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 243.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,447,922 shares of the company's stock after acquiring an additional 1,026,291 shares during the quarter. Cubist Systematic Strategies LLC's holdings in Haleon were worth $14,899,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Royal Bank of Canada grew its holdings in Haleon by 1.5% during the first quarter. Royal Bank of Canada now owns 2,775,678 shares of the company's stock worth $28,561,000 after purchasing an additional 42,063 shares during the period. Sculptor Capital LP grew its holdings in Haleon by 22.1% during the first quarter. Sculptor Capital LP now owns 10,849,868 shares of the company's stock worth $111,645,000 after purchasing an additional 1,962,770 shares during the period. Baird Financial Group Inc. grew its holdings in Haleon by 264.6% during the first quarter. Baird Financial Group Inc. now owns 69,350 shares of the company's stock worth $714,000 after purchasing an additional 50,328 shares during the period. Vident Advisory LLC grew its holdings in Haleon by 158.3% during the first quarter. Vident Advisory LLC now owns 173,249 shares of the company's stock worth $1,783,000 after purchasing an additional 106,183 shares during the period. Finally, Evergreen Capital Management LLC grew its holdings in Haleon by 31.8% during the first quarter. Evergreen Capital Management LLC now owns 51,939 shares of the company's stock worth $534,000 after purchasing an additional 12,540 shares during the period. Institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

Shares of NYSE:HLN traded down $0.06 during trading on Friday, reaching $9.78. 14,727,398 shares of the stock were exchanged, compared to its average volume of 7,557,923. Haleon PLC Sponsored ADR has a 12 month low of $8.86 and a 12 month high of $11.42. The firm has a market cap of $43.84 billion, a PE ratio of 25.07, a PEG ratio of 2.90 and a beta of 0.24. The stock has a 50-day moving average price of $9.78 and a 200-day moving average price of $10.21. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48.

Haleon Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Thursday, September 18th. Investors of record on Friday, August 15th will be paid a $0.0555 dividend. This represents a dividend yield of 190.0%. This is an increase from Haleon's previous semi-annual dividend of $0.05. The ex-dividend date is Friday, August 15th. Haleon's dividend payout ratio is presently 28.21%.

Wall Street Analyst Weigh In

A number of research firms recently commented on HLN. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target for the company in a report on Tuesday, May 27th. BNP Paribas upgraded Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. Morgan Stanley upgraded Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target for the company in a report on Friday, May 9th. Finally, Wall Street Zen cut Haleon from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.33.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.